About Inactive peptidyl-prolyl cis-trans isomerase FKBP6
Inactive peptidyl-prolyl cis-trans isomerase FKBP6 (FKBP6) is a protein
from Homo sapiens identified by UniProt accession
O75344, 327 residues long.
MolForge cross-references it against 0 known binders and
117 disease associations.
Target properties
| Protein name | Inactive peptidyl-prolyl cis-trans isomerase FKBP6 |
|---|
| UniProt accession | O75344 |
|---|
| Gene | FKBP6 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 327 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (117)
Diseases linked to this target (Open Targets).
- male infertility · score 0.48
- body height · score 0.28
- breast adenocarcinoma · score 0.24
- head and neck squamous cell carcinoma · score 0.23
- neurodegenerative disease · score 0.21
- genetic disorder · score 0.19
- triglyceride measurement · score 0.18
- cutaneous melanoma · score 0.15
- squamous cell lung carcinoma · score 0.10
- azoospermia · score 0.10
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O75344-F1 | alphafold | PREDICTED | 90.33 | — |
Amino-acid sequence (327 residues)
MGGSALNQGV LEGDDAPGQS LYERLSQRML DISGDRGVLK DVIREGAGDL VAPDASVLVK YSGYLEHMDR PFDSNYFRKT PRLMKLGEDI TLWGMELGLL SMRRGELARF LFKPNYAYGT LGCPPLIPPN TTVLFEIELL DFLDCAESDK FCALSAEQQD QFPLQKVLKV AATEREFGNY LFRQNRFYDA KVRYKRALLL LRRRSAPPEE QHLVEAAKLP VLLNLSFTYL KLDRPTIALC YGEQALIIDQ KNAKALFRCG QACLLLTEYQ KARDFLVRAQ KEQPFNHDIN NELKKLASCY RDYVDKEKEM WHRMFAPCGD GSTAGES
Explore Inactive peptidyl-prolyl cis-trans isomerase FKBP6 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets